6.3.4. treatment locally-advanced pca. absence high-level evidence, sr could define optimal treatment option . randomised controlled trials available ebrt. local treatment combined systemic treatment provides best outcome, provided patient fit enough receive both. initial results scpg-15 trials suggested randomisation surgery ebrt feasible, oncologic outcomes awaited . 6.3.4.1. radical prostatectomy surgery locally-advanced disease part multi-modal therapy reported . however, comparative oncological effectiveness rp part multi-modal treatment strategy vs. upfront ebrt adt locally-advanced pca remains unknown, although prospective phase iii rct (spcg-15) comparing rp (with without adjuvant salvage ebrt) primary ebrt adt among patients locally-advanced (t3) disease currently recruiting . data retrospective case series demonstrated 60% css 15 years 75% os ten years [781,796,797,799-802]. ct3b–t4 disease, pca cohort studies showed 10-year css 87% os 65% . indication rp previously described stages assumes absence clinically detectable nodal involvement (cn0), based conventional imaging. case suspected positive lns rp (initially considered cn0) procedure abandoned since rp may survival benefit patients. intra-operative frozen section analysis justified case . 6.3.4.2. treatment cn1 m0 pca lymph-node metastasised pca entity options local therapy systemic therapies overlap. approximately 5% 10% newly diagnosed pca patients synchronous suspected pelvic nodal metastases conventional imaging (ct/bone scan) without bone visceral metastases (cn1 m0 stage). meta-analyses shown psma-pet/ct prior primary treatment advanced pca detected disease outside prostate 32% cases despite prior negative conventional imaging using bone scan pelvic ct/mri . rct assessing psma-pet/ct staging tool high-risk pca confirmed findings showed 32% increase accuracy compared conventional imaging detection pelvic nodal metastases . notably, sensitive imaging also caused stage shift cases classified min1, with, average, lower nodal disease burden. management cn1m0 pca historically based long-term adt combined local treatment. benefit adding local treatment assessed various retrospective studies, summarised one sr including five studies [806-810]. results sr confirmed . findings retrospective analysis suggested advantage os css local treatment (rt rp) combined adt compared adt alone. limited evidence exists supporting rp cn1 patients. moschini et al., compared outcomes 50 patients cn+ 252 patients pn1, cn0 pre-operative staging. cn+ significant predictor css . addition brachytherapy boost adt plus ebrt associated improved os retrospective study 1,650 cn1 patients multivariable adjustment propensity score matching . intensification systemic treatment (abiraterone acetate, docetaxel, zoledronic acid) assessed unplanned sub-group analyses stampede multi-arm rct stratifying cn1 m1 status . analyses balanced nodal involvement planned rt use stampede randomisation analysis. abiraterone acetate associated non-significant os improvement (hr: 0.75, 95% ci: 0.48–1.18) non-metastatic patients (n0/n+m0), os data still immature low number events. furthermore, underpowered subgroup analysis hypothesis generating best. moreover, subgroup analyses performed according metastatic/non-metastatic status nodal status (any m) without specific data n1m0 population (n = 369; 20% overall cohort). would apply docetaxel arm stampede trial specific subgroup analysis newly diagnosed n1m0 pca (n = 171, 14% overall cohort) performed. however, addition docetaxel, zoledronic acid, combination, provide os benefit stratifying m0 n+ status. afu-getug 12 trial comparing impact docetaxel plus estramustine addition adt, 29% included high-risk non-metastatic pca patients nodal involvement (pn1) randomisation . non-significant trend towards better relapse-free survival rates reported treatment arm (hr 0.66; 86 0.43–1.01) without os benefit. meta-analysis docetaxel trials n0/n1-m0 patients concluded 8% 4-year survival advantage docetaxel compared adt alone terms failure-free survival without os benefit . two rcts stampede platform protocol reported men de novo high-risk/locally-advanced m0 disease, relapse primary curative therapy high-risk features. thirty-nine percent patients (n = 774) n1 conventional imaging . radiotherapy addition long-term adt administered 71% patients. given mfs os benefits observed overall population (see section 6.3.4.2), combined adt (for 3 years) additional abiraterone (for 2 years) soc cn1 patients addition prostate- wprt. table 6.3.4.1: selected studies assessing local treatment (any ct) cn1 m0 prostate cancer patients studyndesignstudy period/follow-uptreatment armseffect survivalbryant, et al. 2018 648retrospective(national veterans affairs)2000-201561 mo.adt ± ebrtsignificant benefit combined treatment psa levels less median (26 ng/ml)all-cause mortality hr: 0.50 css, hr: 0.38sarkar, et al. 2019 741retrospective(national veterans affairs)2000-201551 mo.adt ± local treatment (surgery rt)significant benefit rpall cause mortality hr 0.36css, hr: 0.32no statistical difference rp vs. rt (p > 0.1)all-cause mortality hr: 047css, hr: 0.88lin, et al.2015 983 propensity score matchingretrospective (ncdb)2004-200648 mo.adt ± ebrtsignificant benefit combined treatment5-yr os: 73% vs. 52%hr: 0.5tward, et al. 2013 1,100retrospective (seer)1988-200664 mo.ebrt(n = 397) vs. ebrt(n = 703)no information adt)significant benefit ebrt5-yr css 78% vs. 71%hr: 0.665-yr. os: 68% vs. 56%,hr: 0.70rusthoven,et al. 2014 796retrospective (seer)1995-200561 mo.ebrt vs. ebrt (no information adt)significant benefit ebrt10-yr os: 45% vs. 29%hr: 0.58seisen, et al. 2018 1,987retrospective (ncdb)2003-201150 mo.adt ± local treatment (surgery rt)significant benefit combined treatment5-yr os: 78.8% vs. 49.2%hr: 0.31no difference rp rtjames, et al. 2016 177unplanned sub-group analysis rct2005-201417 mo.adt ± ebrtsignificant benefit combined treatment5-yr os: 93% vs. 71%2-yr ffs: 81% vs 53%ffs, hr: 0.48elumalai et al. 337retrospective4 centres uk2022-2019adt +/- ebrtsignificant benefit combined treatment5-yr.os: 87% vs. 56% hr: 0.275-yr. bpfs: 74.1% vs. 34.2% hr: 0.33 adt = androgen deprivation therapy; css = cancer-specific survival; ebrt = external beam radiotherapy;ffs = failure-free survival; hr = hazard ratio; mo = months; n = number patients; os = overall survival;rp = radical prostatectomy; rt = radiotherapy; yr = year. 6.3.4.3. options surgery radiotherapy primary treatment 6.3.4.3.1. investigational therapies currently cryotherapy, hifu focal therapies place management locally-advanced pca. 6.3.4.3.2. androgen deprivation therapy monotherapy deferred use adt single treatment modality answered eortc 30891 trial . nine hundred eighty-five patients t0–4 n0–2 m0 pca received adt alone, either immediately symptomatic progression occurrence serious complications. median follow-up 12.8 years, os favoured immediate treatment (hr: 1.21, 95% ci: 1.05–1.39). surprisingly, different disease-free symptom-free survival observed, raising question survival benefit. locally-advanced t3–t4 m0 hspc unsuitable surgery rt, immediate adt may benefit patients psa > 50 ng/ml psa-dt < twelve months symptomatic . median time start deferred treatment 7 years. deferred treatment arm 25.6% patients died without needing treatment. 6.3.4.4. guidelines radical- palliative treatment locally-advanced disease* recommendationsstrength ratingradical prostatectomy (rp)offer rp patients cn0 disease part multi-modal therapy.weakextended pelvic lymph node dissection (eplnd)in patients undergoing lymph node dissection perform extended plnd.strongradiotherapeutic treatmentsoffer patients cn0 disease intensity-modulated radiation therapy (imrt)/volumetric modulated arc therapy (vmat) plus image-guide radiation therapy combination long-term androgen deprivation therapy (adt).strongoffer patients cn0 disease good urinary function, imrt/vmat plus igrt brachytherapy boost (either high-dose rate low-dose rate), combination long-term adt.weakoffer long-term adt least 2 years.strongoffer imrt/vmat plus igrt prostate combination long-term adt two years abiraterone cn0m0 patients ≥ 2 high-risk factors (ct3-4, gleason ≥ 8 psa ≥ 40 ng/ml).strongoffer imrt/vmat plus igrt prostate plus pelvis combination long-term adt two years abiraterone cn1m0 patients.strongtherapeutic options outside surgery radiotherapydo offer whole gland treatment focal treatment.strong *all recommendations based conventional imaging isotope bone scan ct/mr abdomen/pelvis.